ESR1 and breast carcinoma: With the advent of discovering small compounds targeting these receptors [55,56,57,58,59], substantial progress has been achieved in the treatment and prevention of estrogen receptor (ER)+ breast cancer and castration-resistant prostate cancer (CRPC) [60,61,62,63].